Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Operations: 2011-2024

Historic Cash from Operations for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to -$107.7 million.

  • Ptc Therapeutics' Cash from Operations rose 13.89% to -$66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $715.5 million, marking a year-over-year increase of 502.01%. This contributed to the annual value of -$107.7 million for FY2024, which is 32.02% up from last year.
  • Ptc Therapeutics' Cash from Operations amounted to -$107.7 million in FY2024, which was up 32.02% from -$158.4 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Cash from Operations registered a high of -$107.7 million during FY2024, and its lowest value of -$356.7 million during FY2022.
  • Its 3-year average for Cash from Operations is -$207.6 million, with a median of -$158.4 million in 2023.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 96.75% in 2020, then soared by 55.58% in 2023.
  • Ptc Therapeutics' Cash from Operations (Yearly) stood at -$194.1 million in 2020, then fell by 29.51% to -$251.3 million in 2021, then plummeted by 41.91% to -$356.7 million in 2022, then surged by 55.58% to -$158.4 million in 2023, then skyrocketed by 32.02% to -$107.7 million in 2024.